Literature DB >> 18505928

Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene.

Hui-Wen Lo1, Lisa Stephenson, Xinyu Cao, Mira Milas, Raphael Pollock, Francis Ali-Osman.   

Abstract

The glutathione S-transferase P1 (GSTP1) is involved in multiple cellular functions, including phase II metabolism, stress response, signaling, and apoptosis. The mechanisms underlying the significantly high GSTP1 expression in many human tumors are, however, currently not well understood. We report here that the GSTP1 gene is a heretofore unrecognized downstream transcriptional target of the tumor suppressor p53. We identified a p53-binding motif comprising two consecutive half-sites located in intron 4 of the GSTP1 gene and is highly homologous to consensus p53-binding motifs in other p53-responsive genes. Using a combination of electrophoretic mobility shift assay and DNase I footprinting analyses, we showed that wild-type p53 protein binds to the GSTP1 p53 motif and luciferase reporter assays showed the motif to be transcriptionally functional in human tumor cells. In a temperature-sensitive p53-mutant cells, levels of both p21/WAF1 and GSTP1 gene transcripts increased time dependently when cells were switched from the inactive mutant state to the wild-type p53 state. Small interfering RNA-mediated reduction of p53 expression resulted in a specific decrease in GSTP1 expression and in tumor cells with mutated p53; adenovirally mediated expression of wild-type p53 increased GSTP1 expression significantly. In a panel of early-passage brain tumor cultures from patients, high levels of GSTP1 transcripts and protein were associated with wild-type p53 and, conversely, low GSTP1 levels with mutant p53. p53 expression knockdown by small interfering RNA increased cisplatin sensitivity. The ability of wild-type p53 to transcriptionally activate the human GSTP1 gene defines a novel mechanism of protecting the genome and, potentially, of tumor drug resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505928      PMCID: PMC2570202          DOI: 10.1158/1541-7786.MCR-07-2105

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  44 in total

1.  Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  G W Xu; C L Nutt; M C Zlatescu; M Keeney; I Chin-Yee; J G Cairncross
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Expression of enzymes and oncogene induced after radiotherapy and/or chemotherapy in patients with brain tumors.

Authors:  Y Yoshii; A Saito; A Hyodo; H Tsurushima; L Sun
Journal:  Hum Cell       Date:  2001-03       Impact factor: 4.174

3.  Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides.

Authors:  Kamal Datta; Preeti Shah; Tapasya Srivastava; Srinivas G Mathur; Parthaprasad Chattopadhyay; Subrata Sinha
Journal:  Cancer Gene Ther       Date:  2004-08       Impact factor: 5.987

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

6.  Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines.

Authors:  F Ali-Osman; D E Stein; A Renwick
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

7.  Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.

Authors:  Genevieve A Andrews; Sichuan Xi; Rebecca G Pomerantz; Charles J Lin; William E Gooding; Abbey L Wentzel; Li Wu; David Sidransky; Jennifer Rubin Grandis
Journal:  Head Neck       Date:  2004-10       Impact factor: 3.147

8.  Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.

Authors:  J Bargonetti; I Reynisdóttir; P N Friedman; C Prives
Journal:  Genes Dev       Date:  1992-10       Impact factor: 11.361

9.  Cyclic AMP mediated GSTP1 gene activation in tumor cells involves the interaction of activated CREB-1 with the GSTP1 CRE: a novel mechanism of cellular GSTP1 gene regulation.

Authors:  Hui-Wen Lo; Francis Ali-Osman
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

10.  Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide.

Authors:  Eric L Snyder; Bryan R Meade; Cheryl C Saenz; Steven F Dowdy
Journal:  PLoS Biol       Date:  2004-02-17       Impact factor: 8.029

View more
  27 in total

1.  High-resolution genome-wide analysis of chromosomal alterations in elastofibroma.

Authors:  Juan Luis García Hernández; Javier Ortiz Rodríguez-Parets; José María Valero; María Asunción Gomez Muñoz; M Rocío Benito; Jesus M Hernandez; Agustín Bullón
Journal:  Virchows Arch       Date:  2010-04-27       Impact factor: 4.064

2.  Altered protein S-glutathionylation identifies a potential mechanism of resistance to acetaminophen-induced hepatotoxicity.

Authors:  David J McGarry; Probir Chakravarty; C Roland Wolf; Colin J Henderson
Journal:  J Pharmacol Exp Ther       Date:  2015-08-26       Impact factor: 4.030

3.  Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.

Authors:  Hui-Wen Lo; Xinyu Cao; Hu Zhu; Francis Ali-Osman
Journal:  Mol Cancer Res       Date:  2010-02-09       Impact factor: 5.852

4.  Modulation of cell death in human colorectal and breast cancer cells through a manganese chelate by involving GSH with intracellular p53 status.

Authors:  Kaushik Banerjee; Satyajit Das; Saikat Majumder; Subrata Majumdar; Jaydip Biswas; Soumitra Kumar Choudhuri
Journal:  Mol Cell Biochem       Date:  2016-12-23       Impact factor: 3.396

5.  Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.

Authors:  Evangelos Kogias; Nadja Osterberg; Brunhilde Baumer; Nikolaos Psarras; Christoph Koentges; Anna Papazoglou; Joseph E Saavedra; Larry K Keefer; Astrid Weyerbrock
Journal:  Int J Cancer       Date:  2011-07-21       Impact factor: 7.396

6.  PNAS-4 expression and its relationship to p53 in colorectal cancer.

Authors:  Bin Zhou; Hui Yan; Yuan Li; Rong Wang; Keling Chen; Zongguang Zhou; Xiaofeng Sun
Journal:  Mol Biol Rep       Date:  2011-05-10       Impact factor: 2.316

7.  EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.

Authors:  Hu Zhu; Xinyu Cao; Francis Ali-Osman; Stephen Keir; Hui-Wen Lo
Journal:  Cancer Lett       Date:  2010-02-13       Impact factor: 8.679

8.  The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases.

Authors:  Hu Zhu; Hui-Wen Lo
Journal:  Curr Genomics       Date:  2010-06       Impact factor: 2.236

9.  A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion.

Authors:  Hui-Wen Lo; Hu Zhu; Xinyu Cao; Amy Aldrich; Francis Ali-Osman
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

Review 10.  Overflow phenomenon in serum lutein after supplementation: a systematic review supported with SNPs analyses.

Authors:  Abdulrahman M Alharbi; Mohammed A Kilani; Tos Tjm Berendschot
Journal:  Int J Ophthalmol       Date:  2021-07-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.